Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094146 · ClinicalTrials.gov registry record · Phase 2
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
A Phase 2 study of Obesity and Primary Insulin Hypersecretion, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 3
- Study locations
NCT00094146: Completed Phase 2 study of Obesity and Primary Insulin Hypersecretion, sponsored by Novartis.
NCT00094146 is a Phase 2 study of Obesity and Primary Insulin Hypersecretion that has completed, run by Novartis. The registered enrollment target is 160 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00094146, a Phase 2 study of Obesity and Primary Insulin Hypersecretion, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is in patients with at least moderate obesity (Body Mass Index \[BMI\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin. The main purpose of the study is to find the lowest dose of Sandostatin LAR® Depot that safely helps overweight people lose weight. The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo.
Conditions Studied
Interventions
- DRUG Sandostatin LAR Depot
Study Locations (3)
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Tennessee
- University of Tennessee - Memphis
Wisconsin
- University of Wisconsin Beers-Murphy Clinical Nutrition Clinic - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00094146 record still lists
NCT00094146 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Sandostatin LAR Depot is the first listed.
NCT00094146 reports a single indexed study location in Louisiana, Tennessee, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00094146 about?
NCT00094146 is a clinical study titled "Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity". This study is in patients with at least moderate obesity (Body Mass Index \[BMI\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss...
What is the current status of trial NCT00094146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2002-01. Estimated completion is 2002-12.
What conditions does trial NCT00094146 study?
This clinical trial studies the following conditions: Obesity, Primary Insulin Hypersecretion.
What interventions are being tested in trial NCT00094146?
The interventions under investigation include: Sandostatin LAR Depot (DRUG).
Who is sponsoring clinical trial NCT00094146?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094146 being conducted?
This trial has 3 study locations across Louisiana, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00094146's enrollment target sits among peer trials
160 359th of 1053 higher than 691 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia